



Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

August 28, 2025

BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 28, 2025-- [Stoke Therapeutics, Inc.](https://www.stoketherapeutics.com/) (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the following upcoming investor conferences:

Cantor Global Healthcare Conference

Date: Thursday, September 4, 2025

Time: 3:20 p.m. ET

Morgan Stanley 23rd Annual Global Healthcare Conference

Date: Tuesday, September 9, 2025

Time: 1:05 p.m. ET

Live webcasts of each event, along with archived replays, will be available in the Investors & News section of Stoke's website at <https://investor.stoketherapeutics.com/>.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit <https://www.stoketherapeutics.com/>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250828755977/en/): <https://www.businesswire.com/news/home/20250828755977/en/>

Stoke Media & Investor Contacts:

Dawn Kalmar

Chief Communications Officer

dkalmar@stoketherapeutics.com

781-303-8302

Doug Snow

Director, Communications & Investor Relations

IR@stoketherapeutics.com

508-642-6485

Source: Stoke Therapeutics, Inc.